NM_000156.6:c.491delG
Variant summary
Our verdict is Pathogenic. The variant received 11 ACMG points: 11P and 0B. PM3PP4_StrongPM2_SupportingPVS1_Strong
This summary comes from the ClinGen Evidence Repository: The NM_000156.6:c.491del (p.Gly164AlafsTer14) variant in GAMT is a frameshift variant predicted to cause a premature stop codon in the last 50 nucleotides of the penultimate exon and therefore to escape nonsense mediated decay. More than 10% of the protein is predicted to be removed. (PVS1_Strong). This variant has been detected in in 7 unrelated individuals with GAMT deficiency, all of whom were homozygous for the variant (PMID:29302074, PMID:32214227, PMID:15234333, PMID:23660394, PMID:15108290) (1pt, PM3). One of these individuals had elevated GAA in plasma, elevated GAA in urine, deficient GAMT enzyme activity (<5% wild-type) in fibroblasts, and significantly reduced creatine peak with present GAA peak on brain MRS (PMID:15234333) and one of these individuals had elevated urine GAA and undetectable GAMT enzyme activity in fibroblasts (PMID:15108290) (PP4_Strong). The highest population minor allele frequency in gnomAD v2.1.1 is 0.0001607 (4/24886 alleles) in the African/African American population, which is lower than the ClinGen CCDS VCEP’s threshold for PM2_Supporting (<0.0004), meeting this criterion (PM2_Supporting). There is a ClinVar entry for this variant (Variation ID: 810628, 2 star review status) with 7 submitters classifying the variant as pathogenic. In summary, this variant meets the criteria to be classified as pathogenic for GAMT deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel (Specifications Version 1.0): PVS1_Strong, PM2_Supporting, PM3, PP4_Strong. (Classification approved by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel on May 25, 2023) LINK:https://erepo.genome.network/evrepo/ui/classification/CA9043627/MONDO:0012999/026
Frequency
Consequence
NM_000156.6 frameshift
Scores
Clinical Significance
Conservation
Publications
- guanidinoacetate methyltransferase deficiencyInheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Ambry Genetics, Orphanet, G2P, ClinGen, Labcorp Genetics (formerly Invitae)
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 11 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_000156.6. You can select a different transcript below to see updated ACMG assignments.
Ensembl Transcripts
| Sel. | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| GAMT | TSL:1 MANE Select | c.491delG | p.Gly164AlafsTer14 | frameshift | Exon 5 of 6 | ENSP00000252288.1 | Q14353-1 | ||
| GAMT | c.761delG | p.Gly254AlafsTer14 | frameshift | Exon 5 of 6 | ENSP00000572533.1 | ||||
| GAMT | TSL:2 | c.491delG | p.Gly164AlafsTer14 | frameshift | Exon 5 of 5 | ENSP00000403536.2 | Q14353-2 |
Frequencies
GnomAD3 genomes AF: 0.0000394 AC: 6AN: 152188Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.0000120 AC: 3AN: 250692 AF XY: 0.0000147 show subpopulations
GnomAD4 exome AF: 0.00000411 AC: 6AN: 1461126Hom.: 0 Cov.: 33 AF XY: 0.00000138 AC XY: 1AN XY: 726868 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000394 AC: 6AN: 152188Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74352 show subpopulations
Age Distribution
ClinVar
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at